



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

ASHDOWN

Application No.: 10/576,981

Filed: 4/24/2006

For: METHOD OF THERAPY

Examiner:

Art Unit: 1636

INFORMATION DISCLOSURE STATEMENT  
(37 C.F.R. §§ 1.97(b)(3) and 1.98)

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The Examiner is requested to consider the references noted on the enclosed Form PTO/SB/08A (Substitute for form 1449A/PTO) during examination of the above-identified application. These references are submitted for the Examiner's consideration and are submitted pursuant to the duty of disclosure under 37 C.F.R. § 1.56. In submitting these references, no representation is made or implied that the references are or are not material to the examination of the application. The Examiner is encouraged to make his or her own determination of materiality.

Should any additional fees and/or any underpayment of fee(s); credit any overpayments be deemed necessary, such fees may be charged to Deposit Account No. 06-0029.


Should the examiner have any questions concerning the relevance of any reference cited in this disclosure, please contact the undersigned attorney.

Dated: March 19, 2007

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'R. Nakashima', is written over a horizontal line.

Richard A. Nakashima  
Registration No. 42,023  
Customer No. 35657



Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A PTO

*(Use as many sheets as necessary)*

Sheet

1

of

20

**Complete if Known**

Application Number

10/576.981: CONFIRMATION 8112

Filing Date

04/24/2006

First Named Inventor

**Ashdown**

**Art Unit**

Examiner Name \_\_\_\_\_

Attorney Docket Number

335252

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 20

**Complete if Known**

Application Number	10/576,981
Filing Date	4/24/2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	14	NORTH, R. J., et al., "Elimination of cycling CD4 suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advance lymphoma" Immunology 1990 71 90-95	
	15	PLANA, MONTERRAT, et al., "Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection" AIDS 2000, 14:1921-1933	
	16	LUTSIK, M. E. CHRISTINE, et al., "Inhibition of CD4+25+ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low Dose Cyclophosphamide, Blood 1st Ed paper, prepublished online 12/9/2004; DOI 10.1182/blood-2004-06-2410	
	17	SAKAGUCHI, SHIMON, et al., "Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance" Volume 182, August 2001, pp 18-32	
	18	NILSSON, JAKOB, et al., "HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS" Blood, 1 December 2006, Vol. 108, No. 12 pg. 3808-3817	
	19	JARNICKI, ANDREW G., et al., "Suppression of Antitumor Immunity by IL-10 and TGF-B-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells" The Journal of Immunology, 2006, 177: 896-904	
	20	LUNDHOLM, PETER, "Immune and Autoimmune Responses to HIV-1 in Mucosa and Other Tissues" The Swedish Institute for Infectious Disease Control, 29 October 1999, kl 9.00	
	21	SAKAGUCHI, SHIMON, et al., "Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance" Immunological Reviews 2001 Vol. 182: 18-32	
	22	TREFZER, UWE, et al., "Vaccination with Hybrids of Tumor and Dendritic Cells Induces Tumor-Specific T-Cell and Clinical Responses in Melanoma Stage III and IV Patients" Int. J. Cancer: 110, 730-740 (2004)	
	23	TAKAHASHI, TAKESHI, et al., "Immunologic Self-Tolerance Maintained by CD25+ CD4+ Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-associated Antigen 4" J. Exp. Med. Volume 192, No. 2, July 17, 2000 303-309	
	24	SUTMULLER, ROGER P. M., et al., "Synergism of Cytotoxic T Lymphocyte-associated Antigen 4 Blockade and Depletion of CD25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses" J. Exp. Med. Volume 194, No. 6, 9-17-2001 823-832	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 20

**Complete if Known**

Application Number	10/576,981; confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	25	SURI-PAYER, ELISABETH, et al., "Differential Cytokine Requirements for Regulation of Autoimmune Gastritis and Colitis by CD4+ CD25+ T Cells" Journal of Autoimmunity (2001) 16, 115-123	
	26	ADACHI, SUSUMU, et al., "A Pilot Study of Paclitaxel and Carboplatin for Recurrent Ovarian Cancer" Oncology Reports 8: 285-288, 2001	
	27	AZIA, MEHAR, M.D., et al., "Evaluation of Cell-Mediated Immunity and Circulating Immune Complexes as Prognostic Indicators in Cancer Patients" Cancer Detection and Prevention, 22(2):87-99 (1998)	
	28	GAMELIN, E, et al., "Long-term weekly treatment of colorectal metastatic cancer with Fluorouracil and leucovorin: results of a multicentric prospective trial of fluouracil dosage optimization by pharmacokinetic monitoring in 152 patients" J. Clin Oncol., 1998 Apr; 16(4): 1470-8, retrieved from the Internet 12/9/2006	
	29	BLASI, GEBBIA V., et al., "Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study, Anticancer Res. 2003 Jan-Feb; 23(1B): 765-71 retrieved from the Internet 12/9/2006	
	30	GIBBS, P., et al., "A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma" Melanoma Res. 2000 Apr; 10(2):171-9 retrieved from the Internet 12/9/2006	
	31	GINOPOULOS, P., et al., "A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIb-IV non-small cell lung cancer (NSCLC). Lung Cancer, 1999 Jan; 23(1):31-7 retrieved from the Internet 12/9/2006	
	32	GLIMELIUS, B., et al., "irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer" Ann Oncol. 2002 Dec; 13(12):1868-73 retrieved from the Internet 12/9/2006	
	33	GOMEZ-BERNAL, A, et al., "Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study" Am J Clin Oncol., 2003 Apr; 26(2):127-31 retrieved from the Internet 12/9/2006	
	34	GOORIN AM, et al., "Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002 Jan 15;20(2):426-33. retrieved from the Internet 12/9/2006	
	35	BLANKE CD, et al., "Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer" J Clin Oncol, 1997 Mar; 15(3):915-20 retrieved from the Internet 12/9/2006	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 20

**Complete if Known**

Application Number	10/576,981 Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	36	CASSINELLO, J. et al., "Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer" Med Oncol. 2003; 20(1): 37-43	
	37	CHAHINIAN, A. P., et al., "Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B" J Clin Oncol, 1993 Aug; 11(8):1559-65	
	38	CHAPMAN, PB, et al., "Clinical results using biochemotherapy as a standard of care in advanced melanoma" Melanoma Res. 2002 Aug; 12(4):381-7	
	39	CHO EK, et al., "Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma" J Korean Med Sci, 2002 Jun; 17(3):348-52	
	40	CHOI TK, et al., "Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy" Cancer, 1984 Feb 1; 53(3): 401-5	
	41	COMELLA P., et al., "Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial, Ann Oncol. 2000 Oct; 11(10):1323-33	
	42	CONSTENIA, M., et al., "Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study, Gastric Cancer. 2002; 5(3):142-7	
	43	COVENS, A., et al., "Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer" Eur J Gynaecol Oncol., 1992; 13(2):125-30	
	44	DIERAS V., et al., "Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann Oncol. 2002 Feb; 13(2):258-66	
	45	DIPAOLA, R.S., et al., Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. Med Sci Monit. 2003 Feb; 9(2):PI5-11	
	46	AGELAKI, S., et al., "Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study." Lung Cancer. 2001 Dec; 34 Suppl 4:S77-80	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 20

**Complete if Known**

Application Number	10/576,981 Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	47	AHMAD, S. A., et al., "Extraosseous osteosarcoma: response to treatment and long-term outcome" J Clin Oncol. 2002 Jan 15;20(2):521-7	
	48	AITINI, E., et al., Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience" Tumori. 2001 Jan-Feb; 87(1):20-4	
	49	AMADORI, D., et al., "Ovarian cancer: natural history and metastatic pattern. Front Biosci. 1997 Jan 1;2:g8-10	
	50	ASHAMALLA, H., et al., Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2003 Mar 1; 55(3):679-87	
	51	ATKINS MB, et al., "A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma." Clin. Cancer Res. 2002 Oct;8(10):3075-81.	
	52	BAFALOUKOS D., et al., "Docetaxel in combination with dacarbazine in patients with advanced melanoma." Oncology. 2002;63(4):333-7.	
	53	BAFALOUKOS D., et al., "Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group." J Clin Oncol. 2002 Jan 15;20(2):420-5.	
	54	BAR SELA, G., et al. "Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction. J Chemother. 2002 Dec;14(6):623-6	
	55	BECK TM, et al. "Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate. Cancer Treat Rep. 1984 Apr;68(4):647-50	
	56	BEDIKIAN AY, et al., "Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy" J Clin Oncol. 1995 Dec;13(12):2865-8	
	57	BEERBLOCK, K, et al., "Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Cancer. 1997 Mar 15; 79(6):1100-5.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 20

**Complete if Known**

Application Number	10/576,981 Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	58	TRIVEDI C., et al., "Weekly 1-hour infusion of paclitaxel: clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer, 2000 Jul 15;89(2):431-6	
	59	TSAVARIS N, et al., "Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A aretrospective study [corrected from prospective]. Anticancer Res. 1997 Sep-Oct;17(5B):3799-802.	
	60	TWELVES, C.J, et al., "A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer. 1994 Nov;70(5):990-3.	
	61	VALDIVIESO M., et al., "GBroadphase II study of vindesine. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):877-9.	
	62	YAMADA, Y, et al., "Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001 Aug;12(8):1133-7.	
	63	YOGELZANG NJ, et al., "Dihydro-5-azacytidine in malignant mesothelioma. a phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997 Jun 1;79(11):2237-42	
	64	ZENG ZC, et al. "Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol. 1998;124(5):275-80.	
	65	TAKEUCI S., et al. "[A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers] Gan To Kagaku Ryoho. 1991 Aug;18(10):1681-9.	
	66	THOMAS, G.W., et al., "Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association. Cancer Chemother Pharmacol. 1994;35(2):165-8.	
	67	SUTTON GP, et al., "A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 1994 Apr; 53(1):24-6.	
	68	SMITHERS, MARK, et al., "Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen" Cancer Immunol Immunother (2003) 52: 41-52	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 20

**Complete if Known**

Application Number	10/576,981 Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	69	SALOMON, BENOIT, et al., "B7/CD28 Costimulation is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that control Autoimmune Diabetes" Immunity, Vol. 12, 431-440, April, 2000.	
	70	READ, SIMON, et al., "Cytotoxic T Lymphocyte-associated Antigen 4 Plays an Essential role in the Function of CD25+CD4+ Regulatory Cells that control Intestinal Inflammation," J. Exp. Med. The Rockefeller University Press Volume 192, Number 2, July 17, 2000 295-302	
	71	PRICE, CHRISTOPHER P., et al., "Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein" Journal of Immunological Methods, (1987) 205-211	
	72	PETERSON, KARIN E., et al., "Novel Role of CD8+ T Cells and Major Histocompatibility Complex Class I Genes in the Generation of Protective CD4+ Th1 Responses during Retrovirus Infection in Mice" Journal of Virology, Aug. 2002, Vol. 76, No. 16, p. 7942-7948	
	73	O'HARA, ROSEMARY, et al., "Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue" Arthritis Res 2000, 2:142-144	
	74	NORTH, R.J., et al., "Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma Immunology 1990 71 90-95	
	75	LOTEM, M., et al., "Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma" British Journal of Cancer (2004) 90, 773-780	
	76	LIUZZO, et al. "The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein In Severe Unstable Angina, The New England Journal of Medicine, Vol. 331(7) Aug 18, 1994. 417-424	
	77	JIN-HWANG Liu, et al., "Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study" Science Direct-Urology, Volume 57, Issue 4, April 2001, pages 650-654	
	78	KIMURA, MOTOHIKO, et al., "Significance of Serum Amyloid A on the Prognosis in Patients with Renal Cell Carcinoma" Cancer 2001;92:2072-5	
	79	EDA, SHINICHI, et al., "Development of a New Microparticle-Enhanced Turbidimetric Assay for C-reactive Protein With Superior Features in Analytical Sensitivity and Dynamic Range Journal of clinical Laboratory Analysis 12:137-144(1998)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 20

**Complete if Known**

Application Number	10/576,981; confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	80	BERD, DAVID, et al., "Treatment of Metastatic Melanoma with Autologous, Hapten-Modified Melanoma Vaccine: Regression of Pulmonary Metastases" Int. J. Cancer: 94, 531-539 (2001)	
	81	BELLI, FILIBERTO, et al., "Vaccination of Metastatic Melanoma Patients with Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings" Journal of clinical Oncology, Vol. 20, No. 20 (October 15), 2002: pp 4169-4180	
	82	SENJU, OSAMU, "Latex Agglutination Photometric Assay (LA- SYSTEM)" JJCLA Vol. 8, No. 1, 1983 Immunology: Mason et al., Proc. Natl. Acad. Sci. USA 93 (1996)	
	83	MODELSKA, ANNA, et al., "Immunization against rabies with plant-derived antigen" Proc. Natl. acad. Sci. USA Vol. 95, pp. 2481-2485, March 1998 Immunology	
	84	MONTGOMERY, DONNA L., et al., "Heterologous and Homologous Protection against Influenza A by DNA vaccination: Optimization of DNA Vectors" DNA and cell Biology, Vol. 12, Number 9, 1993 pp. 777-783	
	85	MUSK, A. W., et al., "Conventional Treatment and its Effect on Survival of Malignant Pleural Mesothelioma in Western Australia" Aust. N.Z. J. Med. (1982) 12, pp. 229-232	
	86	COULIE, PIERRE G., et al., "A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3" PNAS August 28, 2001, Vol. 98, No. 18, pg 10290-10295	
	87	DAVIS, M. R., et al., "Establishment of a Murine Model of Malignant Mesothelioma" Int. J. Cancer: 52, 881-886 (1992)	
	88	HOSOTSUBO, KIKUMI K., et al., "Hyperbilirubinaemia after major thoracic surgery: comparison between open-heart surgery and oesophagectomy" Critical Care Vol. 4 No. 3 pp. 180-187	
	89	KAPUSTA, J., et al., "A plant-derived edible vaccine against hepatitis B virus" FASEB J. 13, 1796-1799 (1999)	
	90	KRUSE, CAROL A., et al., "analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9Lrat gliosarcoma: Allogeneic cytotoxic T lymphocytes prevent tumor take" Proc. Natl. Acad. Sci. USA Vol. 87, pp. 9577-9581, December 1990	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 9 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	91	XIANG, ZHI QUAN, et al., "Vaccination with a Plasmid Vector Carrying the Rabies Virus Glycoprotein Gene Induces Protective Immunity against Rabies Virus" Virology 199, 132-140 (1994)	
	92	YANG, K., et al., "Early Studies on DNA-based immunizations for measles virus" Vaccine, Vol. 15, No. 8, pp. 888-892, 1997	
	93	CARDOSO, A. I., et al., "Immunization with Plasmid DNA Encoding for the Measles Virus Hemagglutinin and Nucleoprotein Leads to Humoral and Cell-Mediated Immunity" Virology 225, 293-299 (1996) Article No. 0603	
	94	BRENNAN, FRANK R., et al., "Chimeric Plant Virus Particles Administered Nasally or Orally Induce Systemic and Mucosal Immune Responses in Mice," Journal of Virology, Feb. 1999, p. 930-938 Vol. 73, No. 2	
	95	CONRY, ROBERT M., et al., "Immune Response to a Carcinoembryonic antigen Polynucleotide Vaccine" Cancer Research 54, 1164-1168 March 1, 1994	
	96	COX, GRAHAM J., et al., "Bovine Herpesvirus 1: Immune Responses in Mice and Cattle Injected with Plasmid DNA" Journal of Virology, Vol. 67, No. 9 Sept. 1993, p. 5664-5667	
	97	DAVIS, HEATHER L. "DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody" Human Molecular Genetics, 1993, Vol. 2, No. 11 1847-1851	
	98	EISENBRAUN, MICHAEL D., et al., "Examination of Parameters Affecting the Elicitation of Humoral Immune Responses by Particle Bombardment-Mediated Genetic Immunization" DNA and Cell Biology, Volume 12, No. 9, 1993 pp. 791-797	
	99	FYNAN, ELLEN F., et al., "DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations" Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 11478-11482, December 1993 Immunology	
	100	HOOD, ELIZABETH, et al., "Plant-based production of xenogenic proteins" Current Opinion in Biotechnology 1999, 10:382-386	
	101	SEDEGAH, MARTHA, et al., "Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein" Proc. Natl. Acad. Sci. USA Vol. 91, pp. 9866-9870, October 1994	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 10 of 20

**Complete if Known**

Application Number	10/576,981; confirmation 8112
Filing Date	4-24-2006
First Named Inventor	ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	102	ULMER, JEFFREY B., et al., "Heterologous protection against influenza by injection of DNA encoding a viral protein" Science March 19, 1993 v259 n5 102 p1745(5)	
	103	WANG, BIN, et al., "Gene inoculation generates immune responses against human immunodeficiency virus type 1" Proc. Natl. Acad. Sci. USA Vol. 90 pp. 4156-4160, May 1993 Immunology	
	104	LOGOTHETIS, CHRISTOPHER J., et al., "Cyclic Chemotherapy with Cyclophosphamide, Doxorubicin, and Cisplatin Plus Vinblastine and Bleomycin in Advanced Germinal tumors" August 1986 The American Journal of Medicine, Volume 81, p. 219-227 XP-002351698	
	105	MARCHAND, MARIE, et al., "Tumor Regressions Observed in Patients with metastatic Melanoma Treated with An Antigenic Peptide Encoded by Gene Mage-3 and Presented by HLA-A1" Int. J. Cancer: 80, 219-230 (1999) XP-002305439	
	106	BERD, DAVID, et al., "Effect of Low Dose Cyclophosphamide on the Immune System of Cancer patients: Depletion of CD4+, 2H4+ Suppressor-inducer T-Cells" Cancer Research 48, 1671-1675, March 15, 1988 XP 000900007	
	107	FISSON, SYLVAIN, et al., "Continuous Activation of Autoreactive CD4+ CD25+ Regulatory T Cells in the Steady State" J. Exp. Med. Vol. 198, No. 5, September 1, 2003 737-746	
	108	WEISS, LAURENCE, et al., "Human immunodeficiency virus--driven expansion of CD4+ CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients" Blood, 15 November 2004, Vol. 104, No. 10 pp. 3249-3256	
	109	HORVATH, MOGDOLNA, et al. "Investigation of circulating Immune Complexes in Patients with Breast Cancer," Oncology 39: 20-22 (1982)	
	110	O'HANLON, DEIRDRE M., et al., "The Acute Phase Response in breast Carcinoma" Anticancer Research 22:1289-1294 (2002)	
	111	WEINSTEIN, P. S., et al., "Acute-Phase Proteins or Tumour Markers: The Role of SAA, SAP, CRP and CEA as Indicators of Metastasis in a Broad Spectrum of Neoplastic Disease" Scand. J. Immunol. 19, 193-198, 1984	
	112	WITTIG, BURGHARDT, et al., "Therapeutic Vaccination against Metastatic Carcinoma by Expression-Modulated and Immunomodified Autologous Tumor Cells: A First Clinical Phase I/II Trial" Human Gene Therapy 12:267-278 (February 10, 2001)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 11 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	113	JIN, OON CHONG, et al., "Adriamycin in the Treatment of Resectible and Irresectible Primary Hepatocellular Carcinoma" Annals Academy of Medicine, april 1980, vol. 9, No. 2	
	114	SOBRERO AF, et al., "Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer" Clin Cancer Res, 1995 Sep; 1(9):955-60	
	115	STATHOPOULOS GP, et al., "Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer, J Clin Oncol. 2002	
	116	SUGIMACHI, K., et al., "A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer. Surg Today. 2000; 30(12):1067-72	
	117	SHIMIZU, Jun, et al., "Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance" Nature Immunology 3, 135-142 (2002) Published online: 22 January 2002	
	118	SHIMIZU J, et al. "Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity" J Immunol. 1999 Nov 15; 163(10):5211-8	
	119	SINNIGE, H. A., et al. "Modification of 5-fluorouracil activity by high-dose methotrexate or leucovorin in advanced colorectal carcinoma" Eur J Cancer. 1990;26(5):625-8	
	120	SMALL EJ, et al., "Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer" Semin Oncol. 2001 Aug; 28(4 Suppl 15):71-6.	
	121	SAVARESE D, et al., "A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780" Semin Oncol. 1999 Oct;26(5 Suppl 17):39-44	
	122	SAVARESE DM, et al. "Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001 May 1;19(9):2509-16	
	123	SCHEITHAUER, W., et al. "Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer" Ann Oncol. 2002 Oct;13(10):1583-9	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 12 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	124	SCHORNAGEL JH, et al., "Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma" J Urol. 1989 Aug;142(2 Pt 1):253-6	
	125	SEHOULI J., et al., "A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy" Ann Oncol. 2002 Nov;13(11):1749-55	
	126	SHERMAN WH, et al., "Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas." Oncology. 2001;60(4):316-21	
	127	RECCHIA F, et al. "Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II study" Anticancer Res. 2002 Mar-Apr;22(2B):1321-8	
	128	REINA JJ, et al., "A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer" cancer chemother Pharmacol. 2003 Oct;52(4):339-45. Epub 2003 Jul 8.	
	129	RETSAS S, et al. "Taxol and vinorelbine: a new active combination for disseminated malignant melanoma" Anticancer Drugs, 1996 Feb; 7(2):161-5	
	130	RODRIGUEZ-GALINDO C, et al., "Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide" J Pediatr Hematol Oncol. 2002 May;24(4):250-5	
	131	ROMERO A, et al., "Vinorelbine as first-line chemotherapy for metastatic breast carcinoma" J Clin Oncol. 1994 Feb;12(2):336-41	
	132	ROMERO A O, "Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer" Am J Clin Oncol. 1998 Feb;21(1):94-8	
	133	ROSE PG, et al. "A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study" Gynecol Oncol. 2003 Feb;88(2):130-5	
	134	ROSENTHAL MA, et al., "Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme" J Neurooncol. 2000 Mar;47(1):59-63	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 13 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	135	SAFRAN H, et al., "Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase II trial." Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):137-41	
	136	SAKATA Y, et al. "Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur, 0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients." Eur J Cancer. 1998 Oct;34(11):1715-20	
	137	PYRHONEN SO, et al., "Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer" Eur J Cancer. 1992;28A(11):1828-32	
	138	RAGHAVAN D, et al., "Phase II trial of carboplatin in the management of malignant mesothelioma" J Clin Oncol. 1990 Jan;8(1):151-4.	
	139	PETRELLI, NJ, et al. "Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma" Cancer Chemother Pharmacol. 1989;23(1):57-60	
	140	PICUS J., et al., "Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results" Semin Oncol. 1999 Oct;26(5 Suppl 17):14-8.	
	141	PINTO C., et al., "Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study." Am J Clin Oncol. 2001 Apr; 24(2):143-7.	
	142	PLANNER R. S., et al., "Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer" Aust N. Z. J. Obstet Gynaecol. 1996 May; 36(2):168-70	
	143	PLANTING A.S., et al., "Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma" Ann Oncol. 1995 Jul;6(6): 613-5	
	144	POHL, J., et al., "Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma" Chemotherapy. 2001 Sept.-Oct; 47(5):359-65	
	145	PORTA C., et al., "5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study." Oncology, 1995 Nov-Dec;52(6):487-91	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 14

of

20

**Complete if Known**

Application Number	10/576,981; confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	146	POSNER, M., et al., "A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma" Am J. Clin Oncol. 1992 Jun; 15(3):239-41.	
	147	OKUNO, S.H., et al., "Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck" Cancer 2002 Apr 15;94(8):2224-31.	
	148	ONIZUKA, S., et al., "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody." Cancer Res. 1999 Jul 1; 59(13):3128-33.	
	149	OZOLS, R.F., et al., "Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer." Cancer Treat Rep. 1984 Oct;68(10):1229-32.	
	150	PACCAGNELLA, A., et al. "Mitomycin C., vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial." Cancer. 1996 Oct. 15; 78(8):1701-7.	
	151	PATT, Y. Z., et al. "Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma" J. Clin Oncol. 2003 Feb 1; 21(3):421-7	
	152	PECTASIDES, D., et al. "First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study." Anticancer Res. 2001 Sep-Oct;21(5):3575-80	
	153	PERNG, R. P., et al. "A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer." Am J Clin Oncol. 2000 Feb;23(1):60-4.	
	154	NYSTROM, M.L. et al. "Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial" Melanoma Res. 2003 Apr;13(2):197-9.	
	155	NERI, B., et al. "Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial." Anticancer Drugs. 2002 Aug;13(7):719-24.	
	156	NERI B., "Results of leucovorin and doxifluridine oral regimen in the treatment of metastatic colorectal cancer" Anticancer Drugs. 1998 Aug;9(7):599-602.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 15 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	157	MURAD, A.M., et al., "Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen." Am J Clin Oncol. 1999 Dec;22(6):580-6.	
	158	NATHAN F. E., et al., "Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma" Cancer 2000 Jan 1;88(1):79-87.	
	159	MURAD, A.M., "Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer." Am J Clin Oncol. 2003 Apr;26(2):151-4	
	160	MORABITO A., et al., "The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and or anthracyclines: a phase I-II study." Breast Cancer Res Treat. 2003 Mar; 78(1):29-36.	
	161	MORRIS, M., et al., "Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix" J. Clin Oncol. 1998 Mar;16(3):1094-8	
	162	MEROPOL, N. J., et al. "Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma." Cancer. 2001 Apr 1;91(7):1256-63.	
	163	MICHELOTTI, A., et al., "Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients." Semin Oncol. 1996 Oct;23(5 Suppl 11):38-40.	
	164	MONNET I., et al., "Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study." Chest. 2002 Jun;121(6):1921-7.	
	165	MCCLAY, E. F., et al., "A Phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma." Am J. Clin Oncol. 1995 Feb;18(1):23-6.	
	166	MARIOTTA, S., et al., "Combined treatment in advanced stages (IIIb-IV) of non-small cell lung cancer." Eur Rev Med Pharmacol Sci. 2002 Mar-Jun;6(2-3):49-54.	
	167	MBIDDE, E.K., et al., "Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma." Cancer Chemother Pharmacol. 1986;18(3):284-5.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 16 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	168	MANETTA A., et al., "Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study." Cancer. 1994 Jan. 1;73(1):196-9.	
	169	LOUVET C., et al. "Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients" J. Clin Oncol. 2002 Dec 1;20(23):4543-8	
	170	LORUSSO, P., et al., "Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma." Am J. Clin Oncol. 1989 Dec;12(6):486-90.	
	171	KINDLER HL, et al., "Edatrexate (10-ethyl-deaza-aminopterin)(NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B." Cancer. 199 Nov. 15;86(10):1985-91.	
	172	KJORSTAD, K., et al., "A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report" Ann Oncol. 1992 Mar;3(3):217-22.	
	173	KOLLMANNSEBERGER, C., et al. "A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer." Br. J. Cancer. 2000 Aug;83(4):458-62	
	174	KORNEK, G. V., et al., "Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor." Br. J. Cancer. 1998 Sep;78(5):673-8	
	175	KORNEK, G. V., et al. "Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br. J. Cancer. 2002 Jun 17; 86(12):1858-63.	
	176	KOSMAS, C., et al. "Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br J Cancer, 2003 Apr 22;88(8):1168-74	
	177	KOUROUSSIS, C., et al. "Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology. 2001;61(1):36-41	
	178	LEUNG, T. W., et al., "Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma" Clin Cancer Res. 1999 Jul; 5(7):1676-81	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 17 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	179	LI, J.D., et al. "[Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer]" Ai Zheng. 2002 Apr;21(4):416-20.	
	180	LISSONI, A., et al. "Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer" Ann Oncol., 1996 Oct;7(8):861-3.	
	181	LORUSSO, P., et al., "Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol. 1989 Dec;12(6):486-90.	
	182	GREM, J. L., et al. "Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma" J. Clin Oncol. 1993 Sep;11(9):1737-45	
	183	GUASTALLA, J. P., et al. "Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulfate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group" Eur J Cancer. 1994;30A(1):45-9.	
	184	GUNDERSEN S, et al., "interferon in combination with vinblastine in advanced malignant melanoma. A phase I-II study." Cancer. 1989 Oct. 15;64(8):1617-9.	
	185	HENSS, H., et al., "Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura." Onkologie. 1988 Jun;11(3):118-20.	
	186	HOFHEINZ R. D., et al., "High-dose 5-fluorouracil/folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study." Onkologie, 2002 Jun;25(3):255-60.	
	187	HUDES, GR, et al., "Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer." J. Clin. Oncol. 1997 Sep; 15(10):3156-63.	
	188	HURTELOUP, P., et al. "Phase II clinical evaluation of doxifluridine." Cancer Treat. Rep. 1986 Jun; 70(6):731-7.	
	189	IBRAHIM, N. K., et al., "Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma." Cancer. 1999 Oct 1;86(7):1251-7.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 18 of 20

**Complete if Known**

Application Number	10/576,981; Confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	190	JEEN, YT, et al. "Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma." Cancer. 2001 Jun 15;91(12):2288-93.	
	191	JEREMIC, B., et al., "Carboplatin and etoposide in advanced colorectal carcinoma. A phase II study." Cancer. 1993 May 1;71(9):2706-8.	
	192	JEREMIC B., et al., "Carboplatin and etoposide in advanced colorectal carcinoma. A phase II study. Cancer. 1993 May 1;71(9):2706-8.	
	193	JOHNSON, D. H., et al. "Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group." Cancer Treat Rep. 1985 Jul-Aug;69(7-8):821-4.	
	194	KAKOLYRIS, S, et al., "First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin." Am J. Clin Oncol. 1999 Dec;22(6):568-72	
	195	KAKOLYRIS, S., et al., "A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors." Oncology. 2002;63(3):213-8.	
	196	KELLY, W.K, et al., "Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer." J. Clin Oncol. 2001 Jan. 1;19(1):44-53.	
	197	KIKUYAMA, S., et al. "Phase II study of mitomycin C, cisplatin and 5-fluorouracil for advanced and recurrent gastric cancer." Anticancer Res. 2002 Nov-Dec;22(6B):3633-6.	
	198	KIM, T.W., et al. "Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer" Ann Oncol. 2002 Dec;13(12):1893-8.	
	199	EINZIG, A. I., "Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer." Ann Oncol. 1994;5 Suppl 6:S29-32.	
	200	EINZIG, A. I., "A phase II study of taxol in patients with malignant melanoma" Invest New Drugs. 1991 Feb;9(1):59-64.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 19 of 20

**Complete if Known**

Application Number	10/576,981; confirmation 8112
Filing Date	4-24-2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Attorney Docket Number	335252

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	201	EINZIG, Al., et al., "Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy" Med oncol. 1996 Jun;13(2):111-7.	
	202	FAIVRE, S., "Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma" Ann Oncol. 2002 Sep;13(9):1479-89	
	203	FALCONE, A., et al., "5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer." Oncology. 2001;61(1):28-35.	
	204	FORASTIERE, A.A., et al., "Cisplatin, vinblastine, and mitoguazone chemotherapy for epidermoid and adenocarcinoma of the esophagus." J. Clin Oncol. 1987 Aug;5(8):1143-9.	
	205	FOUNTZILAS, G., et al. "Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II Study." J. Neurooncol. 1999;45(2):159-65.	
	206	FRASCI, G., et al., "A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients." Oncology. 2002;62(1):25-32	
	207	FREYER, G., et al., "Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy" J. Clin. Oncol. 2003 Jan 1;21(1):35-40. Epub 2003 Jan 1.	
	208	FUMOLEAU, P., et al., "Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy." J. Clin Oncol. 1993 Jul;11(7):1245-52.	
	209	CASSINELLO, J., et al., "Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer." Clin Colorectal Cancer. 2003 Aug; 3(2):108-12.	
	210	BUZAID A.C., et al., "Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases." Melanoma Re. 1998 De;8(6):549-56.	
	211	CALVO, E., et al., "Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer. 2002 Aug;2(2):104-10.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

***(Use as many sheets as necessary)***

Sheet	20	of	20
-------	----	----	----

**Complete if Known**

Application Number	10/576,981; confiramtion 8112
--------------------	-------------------------------

<b>Filing Date</b>	4-24-2006
--------------------	-----------

<i>First Named Inventor</i>	Ashdown
-----------------------------	---------

**Art Unit**

**Examiner Name**

Attorney Docket Number	335252
------------------------	--------

### NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



IFW

PTO/SB/21 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/576,981; Confirmation 8112
Filing Date	04/24/2006
First Named Inventor	Ashdown
Art Unit	
Examiner Name	
Total Number of Pages in This Submission	18
Attorney Docket Number	335252

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 7 Foreign patent references 189 Non-patent literature documents
---	---	---

### Remarks

The Director is hereby authorized to charge any additional fee(s) or any underpayment of fee(s) under 37 CFR 1.16 and 1.17; credit any overpayments to the Deposit Account No. 06-0029

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	FAEGRE & BENSON LLP		
Signature			
Printed Name	Richard A. Nakashima		
Date	3/20/07	Reg. No.	42,023

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Laura S. Mellblom	Date	3-22-07

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.